HPV-based cervical cancer screening- facts, fiction, and misperceptions

Preventive Medicine

Volumn 98, Issue , 2017, Pages 33-35

  Wentzensen, Nicolas ^a   Arbyn, Marc ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

Cervical cancer; Cytology; HPV; Screening

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; EARLY CANCER DIAGNOSIS; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; PAPANICOLAOU TEST; PATIENT HARM; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; ATTITUDE TO HEALTH; FEMALE; ISOLATION AND PURIFICATION; PAPILLOMAVIRIDAE; PROCEDURES; TIME FACTOR; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

EARLY DETECTION OF CANCER; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PAPILLOMAVIRIDAE; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 85014537899     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2016.12.040     Document Type: Article

References (25)

1. Arbyn, M., Ronco, G., Anttila, A., Meijer, C.J., Poljak, M., Ogilvie, G., et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30:Suppl. 5 (2012, Nov 20), F88–F99.
2. Arbyn, M., Verdoodt, F., Snijders, P.J., Verhoef, V.M., Suonio, E., Dillner, L., et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 15:2 (2014, Feb), 172–183.
3. Arbyn, M., Tommasino, M., Depuydt, C., Dillner, J., Are 20 human papillomavirus types causing cervical cancer?. J. Pathol. 234:4 (2014, Dec), 431–435.
4. Franco, E.L., de S, S., Broker, T.R., Stanley, M.A., Chevarie-Davis, M., Isidean, S.D., et al. Human papillomavirus and cancer prevention: gaps in knowledge and prospects for research, policy, and advocacy. Vaccine 30:Suppl. 5 (2012, Nov 20), F175–F182.
5. Gage, J.C., Schiffman, M., Katki, H.A., Castle, P.E., Fetterman, B., Wentzensen, N., et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J. Natl. Cancer Inst., 106(8), 2014, Aug.
6. Giorgi, R.P., Ronco, G., Dillner, J., Elfstrom, K.M., Snijders, P.J., Arbyn, M., et al. Why follow-back studies should be interpreted cautiously: the case of an HPV-negative cervical lesion. Cancer Cytopathol. 124:1 (2016, Jan), 66–67.
7. Habbema, D., Weinmann, S., Arbyn, M., Kamineni, A., Williams, A.E., de Kok, I.M., et al. Harms of cervical cancer screening in the United States and The Netherlands. Int. J. Cancer, 16, 2016, Nov.
8. Health Council of the Netherlands, Population screening for cervical cancer. The Hague: Health Council of the Netherlands, 2011 (No. 2011/07E).
9. Kinney, W., Huh, W., Protection against cervical cancer versus decreasing harms from screening - what would U.S. patients and clinicians prefer, and do their preferences matter?. Prev. Med. 98 (2017), 31–32 (in this issue).
10. Lew, J.B., Simms, K., Smith, M., Kang, Y.K., Xu, X., Caruana, M., et al. National Cervical Screening Program Renewal: Effectiveness Modelling and Economic Evaluation in the Australian Setting. 2013, Medical Services Advisory Committee, Australia (MSAC Application No. 1276(1276)).
11. Meijer, C.J., Berkhof, J., Castle, P.E., Hesselink, A.T., Franco, E.L., Ronco, G., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124:3 (2009, Feb 1), 516–520.
12. Passamonti, B., Gustinucci, D., Giorgi, R.P., Cesarini, E., Bulletti, S., Carlani, A., et al. Cervical human papilloma virus (HPV) DNA primary screening test: results of a population-based screening programme in central Italy. J. Med. Screen., 10, 2016, Sep.
13. Qaseem, A., Humphrey, L.L., Harris, R., Starkey, M., Denberg, T.D., Screening pelvic examination in adult women: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 161:1 (2014, Jul 1), 67–72.
14. Ronco, G., Dillner, J., Elfstrom, K.M., Tunesi, S., Snijders, P.J., Arbyn, M., et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383:9916 (2014, Feb 8), 524–532.
15. Rossi, P.G., Carozzi, F., Federici, A., Ronco, G., Zappa, M., Franceschi, S., et al. Cervical cancer screening in women vaccinated against human papillomavirus infection: recommendations from a consensus conference. Prev. Med. 98 (2017), 21–30 (in this issue).
16. Rozemeijer, K., de Kok, I.M., Naber, S.K., van Kemenade, F.J., Penning, C., van R, J., et al. Offering self-sampling to non-attendees of organized primary HPV screening: when do harms outweigh the benefits?. Cancer Epidemiol. Biomark. Prev. 24:5 (2015 May), 773–782.
17. Tota, J., Bentley, J., Blake, J., Coutlee, F., Duggan, M., Ferenczy, A., et al. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: acting on evidence to change the current paradigm. Prev. Med. 98 (2017), 5–14 (in this issue).
18. Tota, J., Bentley, J., Blake, J., Coutlee, F., Duggan, M., Ferenczy, A., et al. Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening. Prev. Med. 98 (2017), 15–20 (in this issue).
19. Verdoodt, F., Jentschke, M., Hillemanns, P., Racey, C.S., Snijders, P.J., Arbyn, M., Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials. Eur. J. Cancer 51:16 (2015, Nov), 2375–2385.
20. von Karsa, L., Arbyn, M., De Vuyst, H., Dillner, J., Dillner, L., Franceschi, S., et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 1 (2015), 22–31.
21. Wentzensen, N., Schiffman, M., Filling a gap in cervical cancer screening programmes. Lancet Oncol. 15:3 (2014, Mar), 249–251.
22. Wentzensen, N., Schiffman, M., Dunn, T., Zuna, R.E., Gold, M.A., Allen, R.A., et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int. J. Cancer 125:9 (2009, Nov 1), 2151–2158.
23. Wentzensen, N., Fetterman, B., Castle, P.E., Schiffman, M., Wood, S.N., Stiemerling, E., et al. p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women. J. Natl. Cancer Inst., 107(12), 2015, Dec, djv257.
24. Wentzensen, N., Schiffman, M., Palmer, T., Arbyn, M., Triage of HPV positive women in cervical cancer screening. J. Clin. Virol. 76:Suppl. 1 (2016, Mar), S49–S55.
25. World Health Organization, Comprehensive Cervical Cancer Control: A Guide to Essential Practice. http://appswhoint/iris/bitstream/10665/144785/1/9789241548953_eng pdf?ua=1, 2014.